3L+ DLBCL Treatment Landscape

Patients need options in 3L+ DLBCL that are
efficacious, tolerable, and accessible1

35% of DLBCL patients who relapsed or were refractory to second-line treatment received third-line treatment.

of DLBCL patients who relapsed or were refractory to 2L received 3L treatment2,3

The treatment landscape is rapidly evolving, and statistics may not reflect current outcomes.

By 3L+, patients have a poor prognosis, facing low response and worsening survival rates with each subsequent line of therapy4

  • Patients who relapse post-2L ASCT have rapid disease progression4
  • Patients who relapse post-3L CAR T experience poor outcomes5-7
R-­CHOP or other treatments are used to treat first-line DLBCL patients. ASCT, CAR T, CIT and other systemic therapies are used to treat second-line DLBCL patients. A standard of care for third-line + DLBCL patients does not exist. Currently, third-line DLBCL patients are treated with CAR T, CIT, clinical trials and novel agents.

The currently approved 3L+ DLBCL treatments may not be suitable for all patients due to both clinical and nonclinical factors, including1,9-11:

  • Comorbidities
  • Logistics or manufacturing
  • Insufficient care partner support
  • Total cost of care to patient

While some patients with 3L+ DLBCL may achieve remission, the approved options are not always accessible or effective for all patients12,13

1L=first line; 2L=second line; 3L=third line; ASCT=autologous stem cell transplant; CAR T=chimeric antigen receptor T‑cell; CIT=chemoimmunotherapy; DLBCL=diffuse large B‑cell lymphoma; Pola-R-CHP=polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.

Learn more about a treatment option for 3L+ DLBCL

FIND OUT MORE